Drug Database
IV

IVIG (BT 681 5% / IVIG 5%, Biotest / IVIG 10%, Biotest)

✓ Approved

Grifols, S.A. · 单克隆抗体 · 单克隆抗体

什么是 IVIG?

IVIG 是一种单克隆抗体,由Grifols, S.A.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名BT 681 5%, IVIG 5%, Biotest, IVIG 10%, Biotest
公司Grifols, S.A.
药物类别单克隆抗体, 多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

IVIG 针对 8 个适应症,涉及 5 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersChronic inflammatory demyelinating polyradiculoneuropathy✓ Approved
Immune system disordersSelective IgG subclass deficiency✓ Approved
Nervous system disordersMultifocal motor neuropathy✓ Approved
Nervous system disordersGuillain-Barre syndrome✓ Approved
Blood and lymphatic system disordersThrombocytopenia✓ Approved

注册免费账户还可查看另外 3 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedThe American journal of case reports2026-07-27

Pre-Capillary Pulmonary Hypertension in a Patient With Idiopathic Inflammatory Myopathy Without Extensive Pulmonary Involvement.

Nwokeocha Steve O SO, Abduova Liana L, Thiruvarudchelvam Shalini S, Chaudhary Ashlesha A et al.

BACKGROUND Dermatomyositis is an idiopathic inflammatory myopathy (IIM) that presents commonly with cutaneous, myopathic, and systemic manifestations. Cardiopulmonary involvement is usually paired with interstitial lung disease (ILD), which when severe can lead to pulmonary hypertension (PH) with heart failure, contributing to morbidity, poor quality of life, and mortality. However, dermatomyositis is rarely associated with PH in the absence of extensive ILD, and is infrequently considered in patients who present PH in the absence of significant lung findings. CASE REPORT We present the case of a 71-year-old woman who was admitted with signs and symptoms of heart failure after months of progressive dysphagia, proximal muscle weakness, and shortness of breath. She was subsequently diagnosed with dermatomyositis, as well as pre-capillary PH, through right-heart catheterization, but had no features of extensive ILD on imaging. She was treated with intravenous diuretics, intravenous methylprednisolone 1 g daily for 3 days, followed by oral prednisone 60 mg, and 2 doses of 75 g of intravenous immunoglobulins (IVIG), resulting in overall clinical improvement. Further IVIG treatment and re-evaluation of the need for vasodilator therapy was planned, but unfortunately the patient died following admission with hyperosmolar hyperglycemia and aspiration pneumonia after declining resuscitation and intubation. CONCLUSIONS PH in the absence of extensive ILD in dermatomyositis may be under-recognized. IIM evaluation should be considered in the rheumatological work-up of pre-capillary and combined pre-/post-capillary PH within the appropriate clinical context. Gaps exist in the understanding of the pathophysiology of PH in IIMs and its management, prognosis, and outcomes.

PMID 42503424
阅读全文 →
PubMedCureus2026-07-26

Paraneoplastic Opsoclonus Without Myoclonus Secondary to High-Grade Serous Carcinoma in an Adult.

Bowman Caleb C, Mustafa Ibrahim I

Opsoclonus is a rare disorder characterized by chaotic, multidirectional eye movements and most commonly presents as part of the opsoclonus-myoclonus syndrome (OMS). Although typically described in pediatric populations, particularly in association with neuroblastoma, adult presentations are exceptionally rare and are most often paraneoplastic or infectious in origin. We describe the case of a woman in her 60s who developed isolated opsoclonus associated with a newly diagnosed poorly differentiated metastatic high-grade serous carcinoma. The clinical course, diagnostic evaluation, antibody profiling, and immunomodulatory treatments, including intravenous immunoglobulin (IVIG), corticosteroids, and plasmapheresis, are reviewed. This case highlights the diagnostic challenges and therapeutic considerations associated with adult-onset paraneoplastic opsoclonus.

PMID 42502514
阅读全文 →
PubMedCureus2026-07-26

An Exceptional Preaortic Ectopic Type B2 Thymoma as the Cause of Refractory Myasthenia Gravis: A Case Report.

Elmejdoubi Douaa D, Azzou Oumayma O, Zakaria Yasmina Y, Zouidine Imane I et al.

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder mediated by autoantibodies directed against acetylcholine receptors (anti-AChRs), in which thymic pathology plays a central pathogenic role. While thymomas predominantly arise in the anterior mediastinum, ectopic locations represent a rare and clinically distinct entity. Among these, preaortic ectopic thymomas are exceedingly rare, and their association with refractory MG has not previously been described. We report a 48-year-old woman with generalized MG with bulbar predominance, presenting with an eight-month history, confirmed by markedly elevated anti-AChR antibodies (91.1 nmol/L), a positive neostigmine test, and a pathological decrement exceeding 10% on repetitive nerve stimulation across three nerve-muscle pairs. The patient experienced a life-threatening myasthenic crisis requiring ICU admission and failed to achieve sustained remission despite corticosteroids, pyridostigmine, intravenous immunoglobulins (IVIg), and two cycles of rituximab (1000 mg at day 1 and day 15, followed by 1000 mg at six months), fulfilling criteria for refractory MG. After repeated immunotherapy failures and a normal chest X-ray, a prior external CT, initially interpreted as normal or possibly representing ectopic thyroid tissue, was followed by a dedicated thoracic CT at our institution, which identified a left-lateralized anterior mediastinal soft-tissue mass in close preaortic contact with the ascending aorta (42 × 28 × 41 mm). Complete surgical resection via median sternotomy was performed. Histopathological investigation confirmed a WHO type B2 thymoma (2021 WHO classification), with identification of Hassall's corpuscles confirming the thymic origin of the mass. The patient achieved complete clinical remission (Besinger score 100/100; MGC score 0/50) following postoperative IVIg and was subsequently tapered off corticosteroids. This case highlights the necessity of systematic thoracic CT in all refractory MG regardless of plain radiograph findings and prior imaging reports and underscores the potential importance of complete surgical excision of preaortic ectopic thymic tissue in achieving disease control. Following a systematic search of PubMed, Scopus, and Google Scholar, we did not identify any previously reported case of a WHO type B2 preaortic ectopic thymoma described as the underlying cause of refractory generalized MG.

PMID 42502546
阅读全文 →
PubMedMedicine2026-07-25

Longitudinal changes in inflammatory markers and body weight in adults with primary immunodeficiency receiving immunoglobulin replacement therapy: A retrospective cohort study.

Akgul Balaban Yasemin Y, Inan Mustafa Ilker MI, Kalkan Fikriye F, Sonmez Ezgi E et al.

Immunoglobulin replacement therapy (IgRT) is the cornerstone of treatment for adults with primary immunodeficiency [primary immunodeficiency diseases (PID)]. Its role in infection prevention is well established. However, its effects on systemic inflammation and metabolic parameters remain incompletely understood. This study evaluated one-year changes in inflammatory indices and body weight in adults with PID receiving intravenous (IVIG) or subcutaneous (SCIG) immunoglobulin therapy. This retrospective study included 32 adults with PID. The cohort consisted predominantly of patients with common variable immunodeficiency, along with selected cases of Good syndrome and CTLA-4 insufficiency. Patients received intravenous immunoglobulin (IVIG) (n = 22) or SCIG (n = 10). Inflammatory markers [neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), neutrophil count] and body weight were assessed at baseline and after 12 months. Non-parametric tests were used due to sample size. Body weight increased significantly in both the IVIG (P = .01) and SCIG (P = .011) groups. In the IVIG group, CRP (P = .005), absolute neutrophil count (P = .017), and NLR (P = .034) decreased significantly. In the SCIG group, body weight increased significantly. However, changes in inflammatory markers were not significant. Platelet counts decreased (P = .012), while WBC counts increased (P = .016). IgRT was associated with increased body weight in adults with PID. This was consistent across both IVIG and SCIG groups. IVIG was also associated with reductions in inflammatory markers. These findings suggest that IgRT may have effects beyond infection prevention. Body weight may be a useful parameter during follow-up of adult PID patients.

PMID 42499116
阅读全文 →
PubMedFrontiers in neurology2026-07-25

Anti-NMDA-receptor encephalitis and MOGAD associated optic neuritis: a case series.

Parthasarathi Pooja P, Dattilo Michael M, Peragallo Jason J

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a well-recognized autoimmune condition that often presents with neuropsychiatric symptoms and seizures. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) often manifests as optic neuritis and, less frequently, as acute demyelinating encephalomyelitis or transverse myelitis. The co-occurrence of anti-NMDAR encephalitis and MOGAD is becoming increasingly recognized, but clinical series remain limited. We present three patients with anti-NMDAR encephalitis and MOGAD optic neuritis (ON): two men, aged 19 and 26, and one woman, aged 36. Clinical presentations, signs, investigations, and management of each case are discussed. The 26-year-old man presented with altered mental status and concurrent vision loss. The 36-year-old woman presented with altered mental status during the encephalitis episode and developed vision loss 4 months after encephalitis. The 19-year-old man with a prior history of altered mental status, diagnosed with NMDA encephalitis 9 years earlier, presented with headache and vision loss. Abnormal T2/FLAIR lesions in the brain and/or spinal cord during the encephalitis episode and unilateral or bilateral optic nerve enhancement during the optic neuritis episode were detected on brain and orbital magnetic resonance imaging (MRI) in all patients. All patients tested positive for cerebrospinal fluid (CSF) anti-NMDAR antibodies during the encephalitis episode and had positive serum MOG titers during the optic neuritis episode. Each patient presented with bilateral, asymmetrically reduced visual acuity and diminished color vision. One patient exhibited bilateral temporal optic nerve pallor, while two patients had bilateral optic nerve edema. The diagnostic work-up revealed positive serum MOG titers (1:100, 1:10,000, and 1:10,000 in the 36/F, 26/M, and 19/M, respectively). The 36-year-old woman was treated with intravenous (IV) steroids, plasma exchange (PLEX), and rituximab during the encephalitis episode. During the optic neuritis episode, she was treated with IV steroids, IV immunoglobulin (IVIG), and rituximab, followed by long-term rituximab maintenance therapy. The 19-year-old man was treated for encephalitis with IV steroids, IVIG, and rituximab. During his optic neuritis episode, he received IV steroids, IVIG, and tocilizumab, followed by long-term tocilizumab maintenance therapy. The 26-year-old man was treated with IV steroids, PLEX, and rituximab during the acute episode, followed by long-term IVIG maintenance therapy. After achieving 2 years of stability that prompted the discontinuation of IVIG, the patient experienced a MOG-IgG-positive relapse 5 months later. This relapse was marked by a seizure-like episode and the appearance of new lesions on MRI. The acute symptoms resolved after treatment with intravenous steroids and IVIG. Subsequently, the patient was initiated on an indefinite maintenance IVIG regimen. Visual acuity in all patients improved to their baseline levels following treatment. This series highlights the emerging overlap between anti-NMDAR encephalitis and MOGAD optic neuritis. Optic neuritis may occur months to years after encephalitis, underscoring the need for careful monitoring of patients with anti-NMDAR encephalitis who develop new visual symptoms. Dual autoimmunity may represent a distinct phenotype with implications for long-term immunotherapy.

PMID 42500388
阅读全文 →
PubMedAmerican journal of medical genetics. Part A2026-07-25

Immune Modulatory Therapy for Severe Dengue Hemorrhagic Fever in a Patient With Mitochondrial Complex I Deficiency: A Case Report.

Iness Audra N AN, Walimbe Ameya S AS, Strouphauer Emily R ER, Hirano Michio M et al.

Dengue virus (DENV) poses a serious global health challenge, particularly in cases of dengue hemorrhagic fever (DHF). Patients with preexisting mitochondrial disorders may be at increased risk for complications due to the specific impact of DENV on mitochondrial-dependent cellular processes and immune function. We describe a 16-year-old male with known mitochondrial complex I deficiency caused by a homozygous likely pathogenic variant in NDUFV1 who subsequently developed DHF. His illness was marked by rapidly worsening weakness, respiratory distress, intracranial hemorrhage, and seizures. His clinical course was further complicated by encephalitis, arachnoiditis, and myelitis requiring extensive immunomodulation. He received corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange (PLEX), which led to improvement and partial recovery of functional status. This case highlights several rare complications of dengue fever, the impact of DENV on mitochondrial function, and underscores the complexity of managing infectious diseases in individuals with underlying mitochondrial disorders.

PMID 42499220
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多IVIG